Valuation anchor switch: How does BaiLi TianHeng iza-bren single-handedly push up the ceiling of global dual-anti ADC?

In March 2026, Baili Tianheng once again demonstrated its “blockbuster” strength with hardcore data.

At the European Lung Cancer Conference (ELCC), results of the Phase II study on the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) with iza-bren combined with PD-1 inhibitors were announced: the median progression-free survival (mPFS) reached 8.2 months, the 12-month overall survival rate (OS rate) was 85.7%, and the target lesion shrinkage rate achieved an impressive 100%. This set of data, regarded as having the “best efficacy in the industry,” instantly triggered a strong reaction in the biopharmaceutical field.

This is not only the world’s first study of ADC combined with PD-1 inhibitors for first-line treatment of ES-SCLC, showcasing Best in Class efficacy data, but more importantly, it provides extensive-stage small cell lung cancer patients with a “chemotherapy-free” option for the first time.

For the capital market, the value of this data has already surpassed the clinical research itself: it signifies that Baili Tianheng’s valuation logic is officially shifting from a linear prediction of “single product profitability” to an exponential reassessment of “platform value.” The year 2026 is a key node in this valuation logic shift.

Breaking the impasse: When “chemotherapy-free” becomes a reality

Among all types of lung cancer, small cell lung cancer (SCLC) is the most aggressive “number one killer,” characterized by rapid growth, early metastasis, and high recurrence rates; by the time patients are diagnosed with extensive-stage small cell lung cancer (ES-SCLC), cancer cells have already spread to both lungs or distant organs. For more than thirty years, clinical treatment options for this type of patient have been extremely limited.

Currently, the standard first-line treatment regimen (SOC) for ES-SCLC is platinum-based chemotherapy combined with PD-1 inhibitors, but this regimen has limited efficacy, requiring further improvement and clinical demand: the median progression-free survival (mPFS) is approximately 5-6 months, and the 1-year overall survival rate (OS) is about 50%-60%, meaning nearly 40% of patients may die within a year of diagnosis. Meanwhile, the side effects of chemotherapy, such as bone marrow suppression, nausea and vomiting, and hair loss, severely reduce the quality of life for patients, making it clinically urgent to develop new treatment strategies that can break through efficacy bottlenecks and achieve chemotherapy-free options.

The Phase II clinical trial data announced by Baili Tianheng— the world’s first ADC combined with PD-1 inhibitors for first-line treatment of ES-SCLC— is a precise response to this core clinical dilemma. This regimen significantly surpasses existing standard therapies in efficacy data, outperforming current three-drug/four-drug combination standard therapies, with core advantages highlighted:

Significant efficacy breakthrough, far exceeding standard therapies: The 2.5mg/kg dose group of iza-bren combined with PD-1 inhibitors improved the mPFS of first-line treatment for ES-SCLC from approximately 5-6 months to 8.2 months, and the 1-year OS rate jumped from approximately 50%-60% to 85.7%, significantly better than existing three-drug or four-drug combination standard regimens, achieving substantial prolongation of survival.

All patients had target lesions shrink, ORR reached 85%: The target lesion shrinkage rate in all enrolled patients reached 100%, meaning all patients achieved a reduction in target lesion volume. This result fully demonstrates the strong tumor-shrinking effect of iza-bren combined with PD-1, with 85% of patients achieving deep remission.

Excellent safety profile, suitable for long-term treatment: The discontinuation rate of iza-bren due to adverse reactions was only 2.4%, with good pulmonary safety and a low incidence of interstitial lung disease (ILD), and no ≥3 grade events occurred. This combination treatment strategy achieves high efficacy while ensuring safety.

For ES-SCLC patients, this regimen offers the dual benefits of chemotherapy-free treatment and superior efficacy, freeing patients from the burdens of chemotherapy side effects while providing them with a longer survival period, achieving a qualitative leap in both survival and quality of life in the treatment of small cell lung cancer.

This breakthrough treatment, which brings tangible clinical benefits to patients, holds value far beyond the innovation of treatment for the single cancer type of ES-SCLC; it also provides a systematic and solid clinical evidence basis for the innovative combination logic of “dual-target ADC + IO,” and lays a strong clinical research foundation for iza-bren’s subsequent expansion into immune combination treatment applications for multiple high-incidence solid tumors, including non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma, paving the way for large-scale clinical promotion.

For iza-bren, which already has a First-in-class innovative background, the breakthrough data from the ES-SCLC clinical study further validates its Best-in-class hardcore strength, making this drug’s “natural blockbuster” qualities even more prominent and refined.

Reshaping: When “broad-spectrum” rewrites valuation logic

If “chemotherapy-free” addresses the pain points of patient experience, then “broad-spectrum” has opened up the valuation ceiling for iza-bren.

From a regulatory progress perspective, the commercialization of iza-bren has entered the sprint stage. In November 2025, the NDA for nasopharyngeal cancer treatment was accepted; in January 2026, the NDA for esophageal squamous carcinoma was accepted again and included in priority review. The company expects to achieve the first indication approval for market launch within 2026. Meanwhile, BMS has initiated three global Phase III clinical trials overseas, covering first-line late-stage triple-negative breast cancer, late-stage non-small cell lung cancer after EGFR-TKI resistance, and treated late-stage metastatic urothelial carcinoma.

From a clinical advancement perspective, iza-bren is expanding comprehensively with a “broad-spectrum anti-cancer” approach. As of the end of 2025, the clinical trials for this drug simultaneously conducted in China and the U.S. have exceeded 40, covering over a dozen high-incidence solid tumors, including lung cancer, breast cancer, esophageal cancer, gastric cancer, nasopharyngeal cancer, urothelial carcinoma, and ovarian cancer. In China alone, there are 10 Phase III registration studies progressing concurrently, seven of which have received breakthrough therapy designation. In February 2026, the Phase III study of advanced triple-negative breast cancer also reached both PFS and OS dual primary endpoints, becoming the third Phase III registration clinical trial to achieve endpoints following nasopharyngeal cancer and esophageal squamous carcinoma.

This embodies the core characteristic of a “natural blockbuster”: one drug treats multiple cancers.

From late-line to first-line, from single drug to combination, from breakthroughs in hard-to-treat tumors to covering more major cancers, iza-bren is completing a transition from a “last-line savior” to a “first-line cornerstone.” Its potential patient population is shifting from millions to tens of millions.

This broad-spectrum characteristic directly drives a reevaluation of the market’s valuation model for the company.

In the past, the market’s valuation of Baili Tianheng primarily anchored on peak sales forecasts for iza-bren, using a linear extrapolation logic—adding the revenue of one indication to another. However, as first-line data for major cancers like small cell lung cancer, non-small cell lung cancer, and breast cancer continue to be released, iza-bren’s clinical potential is showing an “exponential growth” trend. It is no longer just a potential blockbuster drug but has validated the underlying platform of the “dual-target ADC + IO” combination logic.

This platform value is reflected in three dimensions:

First, it replaces traditional chemotherapy, becoming the standard combination drug for first- and second-generation IO. In cancers such as small cell lung cancer, non-small cell lung cancer, and esophageal squamous carcinoma, iza-bren combined with PD-1 has demonstrated efficacy surpassing standard therapies, potentially phasing out chemotherapy’s role in combination regimens.

Second, it synergizes with TKI to become a new generation standard therapy. At the 2025 World Lung Cancer Conference, the data for iza-bren combined with Osimertinib as first-line treatment for EGFR-mutated non-small cell lung cancer was encouraging: the objective response rate reached 100%, with all patients achieving tumor shrinkage. This result is expected to redefine the first-line treatment standards for EGFR-mutated NSCLC.

Third, it advances late-line treatments and new adjuvant/adjuvant therapies for over a dozen epithelial tumors. From nasopharyngeal cancer to esophageal squamous carcinoma, from urothelial carcinoma to ovarian cancer, iza-bren has validated its broad-spectrum anti-tumor activity in multiple cancer types. With ongoing clinical data releases, its potential patient population is moving from millions to tens of millions.

It is based on this platform value that Baili Tianheng’s valuation logic is undergoing profound changes: switching from the single product valuation of “single product profitability” to a multifaceted value reassessment of “platform premium.”

The company’s self-developed ADC, GNC, and ARC technology platforms have constructed a sustainable innovation engine. In addition to iza-bren, the HER2 ADC (BL-M07D1) has entered Phase III clinical trials, already demonstrating superior efficacy compared to DS-8201 in preliminary data; the world’s first GNC multi-specific antibody platform has four pipelines entering clinical trials; the first candidate drug from the ARC platform has also entered clinical stages.

Conclusion

From the $8.4 billion collaboration with BMS in 2023, to the acceptance of NDAs for nasopharyngeal cancer and esophageal squamous carcinoma in 2025, and then to the stunning debut of “the world’s first + chemotherapy-free” data for small cell lung cancer in 2026, every step of Baili Tianheng’s iza-bren is redefining the position of Chinese innovative drugs on the global map.

“Chemotherapy-free” reshapes the cancer treatment landscape, “broad-spectrum” validates platform strength, and Baili Tianheng has long surpassed the Biotech positioning of a single blockbuster product, holding a global entry ticket and accelerating its progress towards becoming an international innovative pharmaceutical company. This upgrade in development logic directly drives a fundamental shift in the valuation anchor: from the linear prediction of iza-bren’s single product profitability to a comprehensive transition to an exponential reassessment of the company’s overall platform value and pipeline combination.

The era of leading Chinese pharmaceutical innovation has arrived, and Baili Tianheng is at the forefront, taking the lead in unfolding the curtain for platform-based valuation reconstruction, setting a new benchmark for the global value reassessment of Chinese innovative drugs.